Standardization of High Sensitivity Minimal Residual Disease Monitoring in Multiple Myeloma: An Experience in Tertiary Cancer Centre

Abstract

Minimal residual disease (MRD) status is the most relevant prognostic marker in multiple myeloma (MM). Recently, IMWG has incorporated MRD-negative status as a criterion to define stringent clinical response (sCR) using next-generation flow cytometry (NGF) i.e. high-sensitivity flow cytometry (HSFC). Herein, we present our experience in the standardization of HSFC and MRD monitoring in MM.